Skip to main content
. 2019 Jun 6;2019:4961768. doi: 10.1155/2019/4961768

Table 4.

Overview of excluded studies that described tools to improve mDSS.

Study N Tool Inputs Outcomes
(Daemen et al. 2009)[61] 55 Genetic integration DNA, CNV Cancer outcome

(Kuru et al. 2013)[59] 50 Diagnostics mpMRI PIRADS

(Zumsteg et al. 2013)[55] 1024 Risk stratification Risk factors, Gleason score, biopsy Risk group

(Beyan et al. 2014) [62] Model Genetic integration SNPs Various

(Kent and Vickers 2015)[60] Model Diagnostics Clinical and tumor features Life expectancy

(Gnanapragasam et al. 2016)[56] 10139 Risk stratification PSA, stage, Gleason score Risk group

(Epstein et al. 2016)[57] 26325 Risk stratification PSA, stage Gleason grade

(Gries et al. 2017)[58] 120 Utility values Utility's 18 health states Utility's 243 heath states

Abbreviations. N: Number of patients; CNV: copy number variation; SNP: single nucleotide polymorphism; PSA: prostate specific antigen; mpMRI: multiparametric magnetic resonance imaging; PIRADS: Prostate Imaging Reporting and Data system.